GlassScriptPhysician profile
Daisy B Reyes
NPI 1518982750
$865.48
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $101 · 2021: $186 · 2022: $102 · 2023: $61.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.84 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.84 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $277.57 | 2019-2023 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $187.03 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $137.02 | 2019-2023 | Rayaldee |
| Amgen INC. | $56.37 | 2019 | |
| Aurinia Pharma U.S., INC. | $49.72 | 2021-2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $34.82 | 2021 | |
| Horizon Therapeutics Plc | $34.05 | 2019 | |
| Fresenius USA Marketing, INC. | $30.68 | 2019-2020 | |
| Amicus Therapeutics, INC. | $25.21 | 2022 | |
| Akebia Therapeutics INC | $19.41 | 2021 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.